Cargando…
Gene therapy of cancer : translational approaches from preclinical studies to clinical implementation /
The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new area...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego, CA :
Academic Press,
�2002.
|
| Edición: | 2nd ed. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Ch. 1. Retroviral vector design for cancer gene therapy
- Ch. 2. Noninfectious gene transfer and expression systems for cancer gene therapy
- Ch. 3. Parvovirus vectors for the gene therapy of cancer
- Ch. 4. Antibody-targeted gene therapy
- Ch. 5. Ribozymes in cancer gene therapy
- Ch. 6. The advent of lentiviral vectors: prospects for cancer therapy
- Ch. 7. Immunologic targets for the gene therapy of cancer
- Ch. 8. Development of epitope-specific immunotherapies for human malignancies and premalignant lesions expressing mutated ras genes
- Ch. 9. Introduction to dendritic cells
- Ch. 10. DNA and dendritic cell-based genetic immunization against cancer
- Ch. 11. RNA-transfected dendritic cells as immunogens
- Ch. 12. In Situ immune modulation using recombinant vaccinia virus vectors: preclinical studies to clinical implementation
- Ch. 13. The use of particle-mediated gene transfer for immunotherapy of cancer
- Ch. 14. Applications of gene transfer in the adoptive immunotherapy of cancer
- Ch. 15. Update on the use of genetically modified hematopoietic stem cells for cancer therapy
- Ch. 16. Clinical applications of tumor-suppressor gene therapy
- Ch. 17. Cancer gene therapy with tumor suppressor genes involved in cell-cycle control.
- Ch. 18. Cancer gene therapy with the p53 tumor suppressor gene
- Ch. 19. Antisense downregulation of the apoptosis-related Bcl-2 and Bcl-xl proteins: a new approach to cancer therapy
- Ch. 20. Gene therapy for chronic myelogenous leukemia
- Ch. 21. Transfer of drug-resistance genes into hematopoietic progenitors
- Ch. 22. Multidrug-resistance gene therapy in hematopoietic cell transplantation
- Ch. 23. Development and application of an engineered dihydrofolate reductase and cytidine-deaminase-based fusion genes in myeloprotection-based gene therapy strategies
- Ch. 24. Protection from antifolate toxicity by expression of drug-resistant dihydrofolate reductase
- Ch. 25. A genomic approach to the treatment of breast cancer
- Ch. 26. Antiangiogenic gene therapy
- Ch. 27. VEGF-targeted antiangiogenic gene therapy
- Ch. 28. Strategies for combining gene therapy with ionizing radiation to improve antitumor efficacy
- Ch. 29. Virotherapy with replication-selective oncolytic adenoviruses: a novel therapeutic platform for cancer
- Ch. 30. E1A cancer gene therapy
- Ch. 31. Preemptive and therapeutic uses of suicide genes for cancer and leukemia
- Ch. 32. Treatment of mesothelioma using adenoviral-mediated delivery of herpes simplex virus thymidline kinase gene in combination with ganciclovir
- Ch. 33. The use of suicide gene therapy for the treatment of malignancies of the brain
- Ch. 34. Case study of combined gene and radiation therapy as an approach in the treatment of cancer.